- Home
- IMCR vs MNKD Comparison
IMCR vs MNKD Comparison
Compare IMCR & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMCR | MNKD |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2016 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IMCR | MNKD |
|---|---|---|
| Price | $29.80 | $2.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $61.82 | $8.64 |
| AVG Volume (30 Days) | 338.3K | ★ 7.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $249,428,000.00 | ★ $348,966,000.00 |
| Revenue This Year | $14.39 | $33.40 |
| Revenue Next Year | $8.19 | $16.48 |
| P/E Ratio | ★ N/A | $124.75 |
| Revenue Growth | ★ 43.05 | 22.23 |
| 52 Week Low | $23.15 | $2.41 |
| 52 Week High | $40.71 | $6.51 |
Technical Indicators
Market Signals| Indicator | IMCR | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 36.46 | 19.10 |
| Support Level | N/A | N/A |
| Resistance Level | $34.35 | $6.18 |
| Average True Range (ATR) | 1.28 | 0.14 |
| MACD | -0.19 | 0.04 |
| Stochastic Oscillator | 12.49 | 2.38 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.